Harris B, Watkins S, Cook N, Walker R F, Read G F, Riad-Fahmy D
Department of Psychological Medicine, Tenovus Institute, University Hospital of Wales, Cardiff, United Kingdom.
Biol Psychiatry. 1990 Apr 15;27(8):897-904. doi: 10.1016/0006-3223(90)90471-d.
The current status of the saliva dexamethasone suppression test (DST) is discussed and results from the literature reviewed. Evidence is presented that demonstrates that the efficacy of the salivary-based test is equal to that of the plasma DST provided that specifically developed radioimmunoassays are used for determination of salivary cortisol. Such evidence relied on measurement of cortisol in 300 matched samples of plasma and saliva provided by patients admitted to a routine psychiatric ward over a 2-year period. The results according to diagnosis (DSM-III categories) were in line with those generally reported. The influence of anticholinergic medication was examined: this had no significant effects on the performance of the plasma or salivary-based DST.
本文讨论了唾液地塞米松抑制试验(DST)的现状,并回顾了文献中的结果。有证据表明,只要使用专门开发的放射免疫测定法来测定唾液皮质醇,基于唾液的检测方法的功效与血浆DST相当。这些证据基于对一家常规精神科病房收治的患者在两年期间提供的300对匹配的血浆和唾液样本中的皮质醇进行测量。根据诊断(DSM-III类别)得出的结果与一般报道的结果一致。研究了抗胆碱能药物的影响:其对血浆或基于唾液的DST的性能没有显著影响。